Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MCRPC (metastatic Castration-resistant Prostate Cancer)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04751929
What this trial is testing

Abemaciclib With or Without Atezolizumab for mCRPC

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute 19
Testing effectiveness (Phase 2)Study completedNCT01867710
What this trial is testing

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Who this might be right for
Prostate Cancer
Janssen Pharmaceutica N.V., Belgium 164
Early research (Phase 1)Looking for participantsNCT06193486
What this trial is testing

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04663997
What this trial is testing

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Who this might be right for
Prostate Cancer
Canadian Cancer Trials Group 200
Not applicableUnknownNCT02922218
What this trial is testing

PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.

Who this might be right for
Advanced Prostate CancerCastration ResistantEnzalutamide
Centro Nacional de Investigaciones Oncologicas CARLOS III 187
Testing effectiveness (Phase 2)Looking for participantsNCT06844383
What this trial is testing

Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

Who this might be right for
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium 126
Testing effectiveness (Phase 2)Ended earlyNCT03437941
What this trial is testing

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Corcept Therapeutics 39
Early research (Phase 1)Looking for participantsNCT05997615
What this trial is testing

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
Astellas Pharma Global Development, Inc. 437
Not applicableLooking for participantsNCT06600802
What this trial is testing

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Who this might be right for
Castration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)
Centre Jean Perrin 120
Testing effectiveness (Phase 2)Looking for participantsNCT06702995
What this trial is testing

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate-Resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Evopoint Biosciences Inc. 307
Testing effectiveness (Phase 2)UnknownNCT06250244
What this trial is testing

177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital 12
Large-scale testing (Phase 3)Active Not RecruitingNCT03706365
What this trial is testing

Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Who this might be right for
Prostate Cancer
Eli Lilly and Company 393
Not applicableStudy completedNCT04425200
What this trial is testing

Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting

Who this might be right for
Prostatic Neoplasms
AstraZeneca 205
Testing effectiveness (Phase 2)Looking for participantsNCT06663007
What this trial is testing

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

Who this might be right for
Prostate CancerCDK12 Gene Mutation
Tianjin Medical University Second Hospital 72
Testing effectiveness (Phase 2)Looking for participantsNCT07567521
What this trial is testing

TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
C Ray Therapeutics 90
Early research (Phase 1)Looking for participantsNCT07581184
What this trial is testing

[225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration Resistant Metastatic Prostate CancerProstate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)+2 more
Aktis Oncology, Inc. 138
Large-scale testing (Phase 3)Looking for participantsNCT06855277
What this trial is testing

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 940
Early research (Phase 1)Looking for participantsNCT05176483
What this trial is testing

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)+8 more
Exelixis 1,394
Large-scale testing (Phase 3)Ended earlyNCT04907227
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 81
Testing effectiveness (Phase 2)Active Not RecruitingNCT02861573
What this trial is testing

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Merck Sharp & Dohme LLC 1,200
Next Page